



21 NOV 2006

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450
www.uspto.gov

NOVARTIS
CORPORATE INTELLECTUAL PROPERTY
ONE HEALTH PLAZA 104/3
EAST HANOVER, NJ 07936-1080

In re Application of LASKY	:	
U.S. Application No.: 10/518,988	:	
PCT Application No.: PCT/IB2003/002794	:	DECISION
Int. Filing Date: 17 June 2003	:	
Priority Date Claimed: 28 June 2002	:	
Attorney Docket No.: ON/4032548A	:	
For: 4-(4-METHYLPIPERAZIN-1-YLMETHYL)...	:	

This is in response to applicant's "Renewed Petition Under 37 CFR 1.137(b)" filed 07 November 2006.

BACKGROUND

On 17 June 2003, applicant filed international application PCT/IB2003/002794, which claimed priority of an earlier United States application filed 28 June 2002. A copy of the international application was communicated to the USPTO from the International Bureau on 08 January 2004. The thirty-month period for paying the basic national fee in the United States expired on 28 December 2004.

On 21 December 2004, applicant filed national stage papers in the United States Designated/Elected Office (DO/EO/US). The submission was accompanied by, *inter alia*, the basic national fee required by 35 U.S.C. 371(c)(1).

On 21 November 2005, the DO/EO/US mailed a Notification of Missing Requirements Under 35 U.S.C. 371 (Form PCT/DO/EO/905), which indicated that an oath or declaration in compliance with 37 CFR 1.497 and a sequence listing in computer readable form must be filed.

International application PCT/IB2003/002794 became abandoned as to the United States for failure to timely respond to the Notification of Missing Requirements.

On 25 July 2006, applicant filed a petition under 37 CFR 1.137(b).

On 17 October 2006, this Office mailed a decision dismissing the 25 July 2006 petition.

On 07 November 2006, applicant filed the present renewed petition under 37 CFR 1.137(b).

DISCUSSION

Under 37 CFR 1.137(b), a petition requesting that an application be revived on the grounds of unintentional abandonment must be accompanied by: (1) the required reply unless previously filed, (2) the petition fee as set forth in 37 CFR 1.17(m), (3) a statement that the entire delay in filing the required reply from the due date for the reply until the filing of a grantable petition was unintentional, and (4) a terminal disclaimer if the application was filed before 08 June 1995.

Applicant has previously satisfied items (2) and (4) above.

With regard to item (1), the required declaration has been provided.

With regard to item (3), although the renewed petition provides a summary of events which purportedly led to the abandonment of the present application, the petition does not include the required statement. A sample statement appears on Form PTO/SB/64pct, which is available at www.uspto.gov/web/forms/sb64pct.pdf.

CONCLUSION

The renewed petition under 37 CFR 1.137(b) is DISMISSED without prejudice.

If reconsideration on the merits of the petition is desired, a proper response must be filed within TWO (2) MONTHS from the mail date of this decision. Any reconsideration request should include a cover letter entitled "Renewed Petition Under 37 CFR 1.137(b)".

Please direct further correspondence with respect to this matter to Mail Stop PCT, Commissioner for Patents, Office of PCT Legal Administration, P.O. Box 1450, Alexandria, Virginia 22313-1450, with the contents of the letter marked to the attention of the Office of PCT Legal Administration.

Bryan Lin

Bryan Lin
PCT Legal Examiner
PCT Legal Office

Telephone: 571-272-3303
Facsimile: 571-273-0459